WIPO logo
الهاتف الخلوي | Deutsch | English | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 |
PATENTSCOPE

البحث في مجموعات البراءات الوطنية والدولية
World Intellectual Property Organization
البحث
 
تصفّح
 
الخيارات
 
أخبار
 
تسجيل الدخول
 
مساعدة
 
maximize
ترجمة آلية
1. (WO2012112626) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERS
ملاحظة: نص مبني على عمليات التَعرف الضوئي على الحروف. الرجاء إستخدام صيغ PDF لقيمتها القانونية

What is claimed is:

1. A method of treating cancer in a subject in need of such treatment, comprising administering a GLP-1 receptor agonist to the subject.

2. The method of claim 1, wherein the GLP-1 receptor agonist is a peptide, polypeptide or protein.

3. The method of claim 2, wherein the GLP-1 receptor agonist is a glucagon-like peptide-1 (GLP-1), a derivative of GLP-1, or an analog of GLP-1.

4. The method of claim 3, wherein the GLP-1 receptor agonist is GLP(7-36)amide comprising the sequence of SEQ ID NO: 1.

5. The method of claim 3, wherein the GLP-1 receptor agonist is selected from the group consisting of liraglutide, albiglutide, semaglutide and taspoglutide.

6. The method of claim 2, wherein the GLP-1 receptor agonist is exenatide, a derivative of exenatide, or an analog of exenatide.

7. The method of claim 6, wherein the GLP-1 receptor agonist is synthetic exenatide peptide comprising the sequence of SEQ ID NO:2.

8. The method of claim 6, wherein the GLP-1 receptor agonist is lixisenatide.

9. The method of any one of claims 1-8, wherein the GLP-1 receptor agonist is provided in a suspension formulation comprising:

(a) a particle formulation comprising the GLP-1 receptor agonist; and

(b) a vehicle formulation,

wherein the particle formulation is dispersed in the vehicle.

10. The method of claim 9, wherein (a) the particle formulation additionally comprises a disaccharide, methionine and a buffer and (b) the vehicle formulation is a nonaqueous, single-phase suspension vehicle comprising one or more pyrrolidone polymers and one or more solvents selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof;

wherein the suspension vehicle exhibits viscous fluid characteristics, and the particle formulation is dispersed in the vehicle.

11. The method of claim 10, wherein the buffer is selected from the group consisting of citrate, histidine, succinate, and mixtures thereof.

12. The method of any one of claims 10-11, wherein the disaccharide is selected from the group consisting of lactose, sucrose, trehalose, cellobiose, and mixtures thereof.

13. The method of any one of claims 10-12, wherein the particle formulation is a spray dried preparation of particles.

14. The method of any one of claims 10-13, wherein the vehicle consists essentially of polyvinylpyrrolidone and benzyl benzoate.

15. The method of claim 14, wherein the vehicle is about 50% solvent and about 50% polymer.

16. The method of any one of claims 10-15, wherein the suspension formulation has an overall moisture content of less than or equal to about 10 wt%.

17. The method of any one of claims 1-16, wherein the GLP-1 receptor agonist is delivered using an implantable osmotic delivery device.

18. The method of any one of claims 1-9, wherein the GLP-1 receptor agonist is provided in an injectable formulation.

19. The method of any one of claims 1-18, wherein one or more beneficial agent in addition to the GLP-1 receptor agonist is delivered to the subject, and the beneficial agent is an anticancer agent, a chemotherapeutic agent, or an antidiabetic agent.

20. The method of claim 19, wherein the additional beneficial agent is delivered using an implantable osmotic delivery device.